Methodology: each issue's direction is a live signal — long/short opens or holds a position, neutral means flat, and every direction change opens, flips, or closes it. Returns are direction-aware (a short gains when the price falls) and compound across positions from first observation to the latest issue. "Price move" is the stock's own raw change, shown separately. Neither represents actual portfolio performance.
Position Historyprofitable since 2026-07-10
- 2026-07-04LongHK$37.56 → open → HK$38.96+3.73%
Brief History (13 issues)
Up 0.98% with RSI at 60.7, above the 20-, 50- and 200-day. CXO order flow is recovering; 19 analysts target HK$48.53 for 24.6% upside — continue holding
Position: +1.0%, consolidating high after a +27.7% month on the CXO recovery theme — hold, don't add
Leading the CXO recovery with a +32.4% month — after this run, no adds before a HK$36 retest; hold
Friday -5.95% to HK$36.98, cut by the same sector knife — but a +23.7% month built a real cushion, still 5.7% above the HK$35 stop. Stay long.
Down 4.4% this morning at HK$37.60 — the other half of the CXO duet is taking hits too, but it sits 6.9% above its HK$35 stop; Asymchem is out, this one isn't, and each discipline runs its own book
Up 0.4% this morning at another high of HK$39.70 — the CXO pas de deux with Asymchem plays on; stop HK$35, holding
Up 2.4% this morning at a fresh high of HK$38.20 — the CXO duo resonates (Asymchem pressing records the same day); stop raised to HK$35, holding
Up 2.4% to HK$37.96, another leg high as the CXO theme strengthened through the storm; stop stays HK$34, holding
Holding (~+9%): acceleration leg, institutional upgrades and buybacks in triple support. Stop raised from HK$32.50 to HK$34 (tight, just above the 20-day); at RSI near 70, no adds — and no preemptive trimming either.
Up 4.0% on a volume breakout; the CXO repair (+21.6% on the month) hit its acceleration leg, the position flipped green — holding
-1.1%, long -3.3%; CXO retesting near the 20-day — exit below HK$32.5
CXO -2.9%, long -2.2%; revenue +16.8%, retesting the year's upper range, hold
A 13.4% week into the year's upper range — CXO recovery plus 16.8% revenue growth re-rating in motion